2 Kainos Medicine Inc Type of business IT

붙임 2. 디렉토리 북 양식(영문) Kainos Medicine, Inc. Type of business ① IT( ), ② BT(O), ③ CT( ) ④ NT( ) ⑤ etc( ) A central business Medical research and chemical research industries Pan-Gyo Address 4 F, Institute Pasteur Korea, 16, 712 beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea CEO Lee, Kisub, Yoo, Sungeun Establishment year Number of employee 27 Sales +82 2 567 7419 Fax Main Telephone number Homepage 2007 +82 2 552 1470 http: //kainosmedicine. com Corporate(institute) introduction o Kainos Medicine is led by researchers who have years of experience and success cases in new drug discovery & development and an executive team who have experience in NASDAQ-listed companies. We receive specialized counsel on project selection, evaluation, and external licensing deals from advisory boards and business development consultants who have skills and flourishing experience in global drug development. Kainos Medicine was established in June 2007 and is currently located at Pangyo Techno Valley. Our company is specialized in discovery of novel drug candidates, and in conducting preclinical and early clinical studies. Our business model is to create profit by developing new drug discovery projects and by transferring resulting technology to leading pharmaceutical companies in Korea as well as overseas at the preclinical and/or early clinical stages. In order to do so, we are utilizing our platform technology to expeditiously and efficiently carry forward with global drug development. Also to minimize the risks and to maximize the possibility of success for commercialization, our company is partnering with global pharmaceutical companies through joint research from the early development stages. Main business(main product, service etc. ) o Parkinson’s Disease, Medication KM-819, unlike the current approaches to the treatment of Parkinson’s disease (PD), is an innovative new drug based on the new mode of action that protects dopaminergic neurons from death by inhibiting the function of FAF 1 which is known to induce cell death. KM-819 showed the efficacy of neuroprotection and inhibiting behavioral impairment induced by MPTP treatment in animals

Main business(main product, service etc. ) At present, there are four classes of therapy for PD, Dopamine supplement therapy (Levodopa), Dopaminergic agonist (Ropinirole), COMT inhibitor (Tolcapone) and MAO-B inhibitor (Selegiline). The pharmacological function of these therapies is limited to relieving PD symptoms but with various complications leading to serious side effects such as insomnia, movement impairment and tremors There has been no drugs available which slow or halt the progression of the disease until our drug KM-819 was discovered. Thus, we hope that KM-819 would be the first-in -class disease modifying therapeutic for Parkinson’s disease. Currently KM-819 completed Phase I clinical study in Korea and is in the middle of preparing Phase II clinical study to prove its effectiveness on Parkinson's disease. o HIV/AIDS Medication Kainos Medicine is developing novel non-nucleoside reverse transcriptase inhibitor (NNRTI) as anti HIV drug. This compound is the same NNRTI class with efavirenz(Sustiva) which is a blockbuster HIV drug marketed by BMS. Efavirenz is known to cause birth defects and should not be used in women who might become pregnant. Kainos conducted a placebo controlled, Single and Multiple Ascending Dose study (SMAD) in healthy volunteers. KM 023 human pharmacokinetics demonstrated that QD dosing is possible covering the K 103 N mutant display improved safety profile relative to efavirenz and has the potential to be combined with other drugs in a single pill. We have completed transfer of technology to the Chinese pharmaceutical company and currently proceeding with a strategic joint development for additional clinical trials and commercialization of KM 023. Phase III clinical study for KM 023 is ongoing in China. o Anti-Cancer Agents • BRD 4 Inhibitor Anti-Cancer Agent A bromodomain, one of promising targets of epigenetics, is a protein domain that recognizes acetylated lysine residues on the N-terminal tails of histones. This recognition is often a prerequisite for protein-histone association and chromatin remodeling. Among the four members of BET (Bromodomain and Extra Terminal domain) family, BRD 3/4 has been associated with the regulation of some genes in cancer area. Through our core competency of medicinal chemistry technology, we have discovered a candidate compound based on the inhibition of BRD 4 (one type of bromodomain) and currently conducting strategic joint development program with the Chinese pharmaceutical company.

Main business(main product, service etc. ) • Cytotoxic Inhibitor Anti-Cancer Agent Ara-C, the standard medicine to treat acute myeloid leukemia, is an anti-cancer agent with a mechanism of action that blocks DNA synthesis and replication, however it has been reported to have no effects on solid tumors. Kainos Medicine tries to overcome the limitation of cytotoxic anti-cancer agents, such as Ara-C, by discovering the best-in-class nucleic acid derivative that are efficacious to hematological cancers and solid tumors and can be taken both orally and through intravenous injection. Through our core competency of medicinal chemistry technology, we have discovered a candidate compound based on the inhibition of BRD 4 (one type of bromodomain) and currently conducting strategic joint development program with the Chinese pharmaceutical company. • Immuno-Oncologic Agent Immuno-oncologic approach is the 3 rd generation anti-cancer treatment that uses a novel mechanism of destroying cancer cells through the activation of patient’s immune system. It does not produce side effects of chemotherapy or resistance from the usage of targeted anti-cancer therapy. It is hope to be efficacious for both of hematological and solid tumors. Immuno-oncologic agents utilize the patient's internal immune system, brings complete cure with little to no side effects. However, it is known to have definite effects only to 25% of the patient population. FDA has approved four immno-oncology drugs, Keytruda, Opdivo, Tecentriq, Yervoy. Kainos Medicine is developing novel small molecule immuno-oncology drugs that modulate anti-cancer abilities of immune cells. Through our core competency of medicinal chemistry technology, we are developing candidates. HBV Medication By grafting our medicinal chemistry and drug development know-hows and Institute Pasteur Korea's basic science research competencies and screening skills, we are conducting a joint research program for the discovery of a novel Hepatitis B (HBV) drug. HBV is an internationally major public health concern, and it is reported that there approximately 240 million patients with chronic hepatitis worldwide. HBV not only causes life-threatening chronic hepatitis, but also known to be the cause of 70% of liver cancer worldwide. Also, HBV is considered to be the primary cause for liver transplantation. According to Korea CDC (Centers for Disease Control and Prevention) and MHW (Ministry of Health and Welfare), the prevalence of HBV in Korea is reported to be 3. 2% for males and 2. 7% for females